New Look at Gene Expression Regulation
Discovery at UVA Offers Unprecedented Look at Regulation of Gene Expression -- New Method Developed for Studying Epigenetics in Single Cells
A groundbreaking new technique developed at the University of Virginia School of Medicine is allowing scientists to examine histone modifications of genetic loci – a process that regulates gene expression – in single cells. The technique enables researchers, for the first time, to analyze the process within the individual cell types that make up complex tissues, overcoming a major limitation of traditional analysis and offering unprecedented opportunities for understanding mechanisms that contribute to development of major human diseases, including cancer, cardiovascular and neurological diseases.
The UVA researchers believe their new technique will have broad
applications for most biomedical areas, including elucidating
mechanisms that contribute to development of complex tissues and how
cells that contain the same genetic material become different from one
another during development. A particularly valuable feature of this new
method is that it can be used to study mechanisms of gene regulation in
single cells in fixed histological sections, including large archives
of human autopsy specimens. Although the method was developed to look
at histone modifications at single gene loci in individual cells, it
can likely be adapted to looking at any protein-DNA interactions.
“It’s extremely important to understand how one set of genetic
material can be differently used by each of the many cell types that
exist in your body – for example, what makes bone cells different from
heart cells, tumor cells different than non-tumor cells,” says UVA’s
Gary K. Owens, PhD. “Our method is going to allow completely new
approaches to addressing these fundamental questions.”
Implications for Atherosclerosis
The new method should greatly advance science’s understanding of
atherosclerosis – hardening of the arteries that contributes to heart
attacks, stroke and hypertension – by allowing groundbreaking
examination of the mechanisms that shape plaque development and whether
a plaque might be vulnerable to rupture, the inciting event for adverse
clinical events. The new technique already has indicated that numerous
studies of atherosclerosis have grossly underestimated the frequency
and role of smooth muscle cells within lesions, the UVA researchers
report.
Epigenetic Breakthrough
UVA’s new method overcomes several limitations of traditional testing
using chromatin immunoprecipitation (ChIP) analysis. Because that form
of analysis does not allow the examination of histone modification at
the level of individual cells – often requiring a million cells or more
– attempts to analyze multicellular tissues lead to murky results. For
example, an analysis of a tumor or atherosclerotic tissue produces a
crude composite of the many different cell types in the sample. “When
ChIP assays are performed on a tumor biopsy sample,” Owens says, “you
get a mixture of signals not only from the cancer cells in that biopsy
specimen but all the normal cells. … Thus the ChIP assay has very
limited usefulness for analyzing normal or pathological tissues.”
UVA’s method, on the other hand, overcomes this problem by combining
two approaches known as in situ hybridization (ISH) and proximity
ligation assay (PLA). The result is an unprecedented look, of
exceptional clarity, at the histones at work shaping individual
cells.
Published in Nature Methods
The new technique is described in an article that has been published
online in the journal Nature Methods. The article will appear in
a forthcoming print edition as well. It was authored by Delphine Gomez,
Laura S. Shankman, Anh T. Nguyen and Owens.
Developing the technique required Gomez, PhD, to take a painstaking
approach to integrating the ISH and PLA methods, with much trial and
error. Yet her methodical work produced positive results remarkably
quickly, considering the complexities involved. “Between the beginning
and the first positive results was six months,” she recalls. She
followed that initial gene with two more in only four weeks,
demonstrating the widespread applicability of the method.
“I remember thinking she accomplished it much faster than I thought
anybody could have,” Owens says.

